UAE-based Mango Sciences, a data science company focused on emerging markets, has secured investment from Spartech Ventures, a Dubai-based venture capital firm. The investment comes as part of Mango Sciences’ current funding round. The amount of the investment was undisclosed.
Launched in GCC last August, Mango is tackling access to precision medicine for populations overlooked in emerging markets. The company uses artificial intelligence (AI) to better understand the cost of care, improve operational efficiencies and enable personalised care for all populations through partnering with hospitals and clinics in Asia and the Middle East to unlock underutilised health insights from complex clinical data.
"We are excited about how Mango's data platform can transform care delivery for people in the GCC, catalysing clinical research and access to truly personalised care for everyone," said Amer Fatayer, managing director of Spartech Ventures.
"Mango’s unique ability to collaborate across the healthcare ecosystem allows us to leverage data to identify unmet need and help finance innovative immunotherapies for patients where affordability is a key issue to access," said Dr Mohit Misra, chief executive officer and co-founder of Mango Sciences.